A randomized phase II study of EMD 121974 in patients (pts) with metastatic melanoma (MM)

8548 Background: EMD 121974 is a selective antagonist of avβ3 integrin, which promotes the proliferation of tumor-associated endothelial cells and potentially the survival of melanoma cells express...